Skip to main content

Advertisement

SpringerLink
Log in

Loss of miR-26a-5p promotes proliferation, migration, and invasion in prostate cancer through negatively regulating SERBP1

  • Original Article
  • Published:
Tumor Biology

Abstract

The biological role of miR-26a involved in the carcinogenesis of prostate cancer (PC) has been controversial. Besides, the underlying mechanism by which miR-26a plays a role in PC has been unclear. To investigate the role of miR-26a-5p in the PC, miR-26a-5p was detected and statistically analyzed in clinical PC tissues and a panel of PC cell lines. Using bioinformatics analysis, we found that serpine1 messenger RNA (mRNA) binding protein 1 (SERBP1) was a potential downstream target of miR-26a-5p. Using luciferase reporter and western blot, we identified that miR-26a-5p negatively regulated SERBP1 on the PC cell line level. It was confirmed that miR-26a-5p was markedly downregulated in PC tissues compared with normal controls whose reduced expression was significantly associated with metastasis and poor overall prognosis and found that miR-26a-5p was able to prevent proliferation and motility of PC cells in vitro. Additionally, SERBP1 was identified as a downstream target of miR-26a-5p. Moreover, it was observed that SERBP1 was markedly upregulated in prostate cancer tissues and was significantly associated with tissue metastasis and Gleason score. Taken together, our results for the first time demonstrate that the loss of miR-26a-5p promotes proliferation, migration, and invasion through targeting SERBP1 in PC, supporting the tumor-suppressing role of miR-26a-5p in PC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Hu Y, Zhao Q, Rao J, Deng H, Yuan H, Xu B. Longitudinal trends in prostate cancer incidence, mortality, and survival of patients from two Shanghai City districts: a retrospective population-based cohort study, 2000-2009. BMC Public Health. 2014;14(1):356.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.

    Article  PubMed  Google Scholar 

  3. Deng J, He M, Chen L, Chen C, Zheng J, Cai Z. The loss of miR-26a-mediated post-transcriptional regulation of cyclin E2 in pancreatic cancer cell proliferation and decreased patient survival. PLoS One. 2013;8(10):e76450.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gao J, Li L, Wu M, Liu M, Xie X, Guo J, Tang H, Xie X. MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1. PLoS One. 2013;8(6):e65138.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ichikawa T, Sato F, Terasawa K, Tsuchiya S, Toi M, Tsujimoto G, Shimizu K. Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. PLoS One. 2012;7(2):e31422.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Jansen MP, Reijm EA, Sieuwerts AM, Ruigrok-Ritstier K, Look MP, Rodriguez-Gonzalez FG, Heine AA, Martens JW, Sleijfer S, Foekens JA, et al. High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res Treat. 2012;133(3):937–47.

    Article  CAS  PubMed  Google Scholar 

  7. Zhang B, Liu XX, He JR, Zhou CX, Guo M, He M, Li MF, Chen GQ, Zhao Q. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis. 2011;32(1):2–9.

    Article  CAS  PubMed  Google Scholar 

  8. Yu L, Lu J, Zhang B, Liu X, Wang L, Li SY, Peng XH, Xu X, Tian WD, Li XP. miR-26a inhibits invasion and metastasis of nasopharyngeal cancer by targeting EZH2. Oncol Lett. 2013;5(4):1223–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Lin Y, Chen H, Hu Z, Mao Y, Xu X, Zhu Y, Wu J, Li S, Mao Q, Zheng X, et al. miR-26a inhibits proliferation and motility in bladder cancer by targeting HMGA1. FEBS Lett. 2013;587(15):2467–73.

    Article  CAS  PubMed  Google Scholar 

  10. Deng M, Tang HL, XH L, Liu MY, XM L, YX G, Liu JF, He ZM. miR-26a suppresses tumor growth and metastasis by targeting FGF9 in gastric cancer. PLoS One. 2013;8(8):e72662.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Zhang Y, Zhang B, Zhang A, Li X, Liu J, Zhao J, Zhao Y, Gao J, Fang D, Rao Z. IL-6 upregulation contributes to the reduction of miR-26a expression in hepatocellular carcinoma cells. Braz J Med Biol Res. 2013;46(1):32–8.

    Article  CAS  PubMed  Google Scholar 

  12. Guo P, Lan J, Ge J, Nie Q, Guo L, Qiu Y, Mao Q. MiR-26a enhances the radiosensitivity of glioblastoma multiforme cells through targeting of ataxia-telangiectasia mutated. Exp Cell Res. 2014;320(2):200–8.

    Article  CAS  PubMed  Google Scholar 

  13. Liu B, Wu X, Wang C, Liu Y, Zhou Q, Xu K. MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. Biochim Biophys Acta. 2012;1822(11):1692–704.

    Article  CAS  PubMed  Google Scholar 

  14. Shen W, Song M, Liu J, Qiu G, Li T, Hu Y, Liu H. MiR-26a promotes ovarian cancer proliferation and tumorigenesis. PLoS One. 2014;9(1):e86871.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Tian L, Fang YX, Xue JL, Chen JZ. Four microRNAs promote prostate cell proliferation with regulation of PTEN and its downstream signals in vitro. PLoS One. 2013;8(9):e75885.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Zhao S, Ye X, Xiao L, Lian X, Feng Y, Li F, Li L. MiR-26a inhibits prostate cancer progression by repression of Wnt5a. Tumour Biol. 2014;35(10):9725–33.

    Article  CAS  PubMed  Google Scholar 

  17. Rodriguez-Antolin A, Gomez-Veiga F, Alvarez-Osorio JK, Carballido-Rodriguez J, Palou-Redorta J, Solsona-Narbon E, Sanchez-Sanchez E, Unda M. Factors that predict the development of bone metastases due to prostate cancer: recommendations for follow-up and therapeutic options. Actas Urol Esp. 2014;38(4):263–9.

    Article  CAS  PubMed  Google Scholar 

  18. Rove KO, Crawford ED. Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival. Oncology (Williston Park). 2011;25(14):1362–70 .1375-1381, 1387

    Google Scholar 

  19. Konishi H, Fujiya M, Ueno N, Moriichi K, Sasajima J, Ikuta K, Tanabe H, Tanaka H, Kohgo Y. MicroRNA-26a and -584 inhibit the colorectal cancer progression through inhibition of the binding of hnRNP A1-CDK6 mRNA. Biochem Biophys Res Commun. 2015;467(4):847–52.

    Article  CAS  PubMed  Google Scholar 

  20. Zhang X, Cheng SL, Bian K, Wang L, Zhang X, Yan B, Jia LT, Zhao J, Gammoh N, Yang AG, et al. MicroRNA-26a promotes anoikis in human hepatocellular carcinoma cells by targeting alpha5 integrin. Oncotarget. 2015;6(4):2277–89.

    Article  PubMed  Google Scholar 

  21. Ma DN, Chai ZT, Zhu XD, Zhang N, Zhan DH, Ye BG, Wang CH, Qin CD, Zhao YM, Zhu WP, et al. MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2. J Hematol Oncol. 2016;9(1):1.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Erdmann K, Kaulke K, Thomae C, Huebner D, Sergon M, Froehner M, Wirth MP, Fuessel S. Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs. BMC Cancer. 2014;14:82.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Darshan M, Zheng Q, Fedor HL, Wyhs N, Yegnasubramanian S, Lee P, Melamed J, Netto GJ, Trock BJ, De Marzo AM, et al. Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network. Prostate. 2014;74(1):61–9.

    Article  CAS  PubMed  Google Scholar 

  24. Song H, Liu Y, Pan J, Zhao ST. Expression profile analysis reveals putative prostate cancer-related microRNAs. Genet Mol Res. 2013;12(4):4934–43.

    Article  CAS  PubMed  Google Scholar 

  25. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology. 2011;77(5):1265 .e1269-1216

    Article  PubMed  Google Scholar 

  26. Borno ST, Fischer A, Kerick M, Falth M, Laible M, Brase JC, Kuner R, Dahl A, Grimm C, Sayanjali B, et al. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov. 2012;2(11):1024–35.

    Article  PubMed  Google Scholar 

  27. Sandhu R, Rivenbark AG, Mackler RM, Livasy CA, Coleman WB. Dysregulation of microRNA expression drives aberrant DNA hypermethylation in basal-like breast cancer. Int J Oncol. 2014;44(2):563–72.

    CAS  PubMed  Google Scholar 

  28. Sandhu R, Rivenbark AG, Coleman WB. Loss of post-transcriptional regulation of DNMT3b by microRNAs: a possible molecular mechanism for the hypermethylation defect observed in a subset of breast cancer cell lines. Int J Oncol. 2012;41(2):721–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Zhou C, Lu Y, Li X. miR-339-3p inhibits proliferation and metastasis of colorectal cancer. Oncol Lett. 2015;10(5):2842–8.

    PubMed  PubMed Central  Google Scholar 

  30. Guo L, Yu J, Yu H, Zhao Y, Chen S, Xu C, Chen F. Evolutionary and expression analysis of miR-#-5p and miR-#-3p at the miRNAs/isomiRs levels. BioMed Res Int. 2015;2015:168358.

    PubMed  PubMed Central  Google Scholar 

  31. Guo L, Zhang H, Zhao Y, Yang S, Chen F. Selected isomiR expression profiles via arm switching? Gene. 2014;533(1):149–55.

    Article  CAS  PubMed  Google Scholar 

  32. Koensgen D, Mustea A, Klaman I, Sun P, Zafrakas M, Lichtenegger W, Denkert C, Dahl E, Sehouli J. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression. Gynecol Oncol. 2007;107(2):266–73.

    Article  CAS  PubMed  Google Scholar 

  33. Serce NB, Boesl A, Klaman I, von Serenyi S, Noetzel E, Press MF, Dimmler A, Hartmann A, Sehouli J, Knuechel R, et al. Overexpression of SERBP1 (plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis. BMC Cancer. 2012;12:597.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Costa FC, Saito A, Goncalves KA, Vidigal PM, Meirelles GV, Bressan GC, Kobarg J. Ki-1/57 and CGI-55 ectopic expression impact cellular pathways involved in proliferation and stress response regulation. Biochim Biophys Acta. 2014;1843(12):2944–56.

    Article  CAS  PubMed  Google Scholar 

  35. Mayer B, Muche R. Formal sample size calculation and its limited validity in animal studies of medical basic research. Tierarztliche Praxis Ausgabe K, Kleintiere/Heimtiere. 2013;41(6):367–74.

    CAS  PubMed  Google Scholar 

  36. Baker M. Reproducibility crisis: blame it on the antibodies. Nature. 2015;521(7552):274–6.

    Article  CAS  PubMed  Google Scholar 

  37. Mari Y, West GM, Scharager-Tapia C, Pascal BD, Garcia-Ordonez RD, Griffin PR. SERBP1 is a component of the liver receptor homologue-1 transcriptional complex. J Proteome Res. 2015;14(11):4571–80.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The study was supported by the Guangdong Natural Science Foundation (No. S201301004644) and the Southern Medical University Supporting Foundation (No. PX2015N015).

Author information

Authors and Affiliations

  1. Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China

    Kai Guo, Shaobo Zheng, Yawen Xu, Abai Xu, Binshen Chen & Yong Wen

Authors
  1. Kai Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shaobo Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yawen Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abai Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Binshen Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yong Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yong Wen.

Ethics declarations

Conflicts of interest

None

Electronic supplementary material

Supplementary table 1

Listed were the siRNA sequences involved against SERBP1. (DOCX 14 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, K., Zheng, S., Xu, Y. et al. Loss of miR-26a-5p promotes proliferation, migration, and invasion in prostate cancer through negatively regulating SERBP1. Tumor Biol. 37, 12843–12854 (2016). https://doi.org/10.1007/s13277-016-5158-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-016-5158-z

Keywords

Search

Navigation